Morgan Stanley reiterated coverage on Cullinan Oncology with a new price target

6/7/21 7:45:51 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley reiterated coverage of Cullinan Oncology with a rating of Overweight and set a new price target of $43.00 from $40.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CGEM

Date	Price Target	Rating	Analyst
6/11/2025	$22.00	Buy	Stifel
10/24/2024	$30.00	Buy	UBS
5/1/2024	$40.00	Buy	Stifel
4/15/2024		Outperform	William Blair
2/15/2024	$30.00	Outperform	Wedbush
6/15/2023		Outperform	TD Cowen
11/21/2022	$20.00	Buy	BTIG Research